JP2019534246A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534246A5 JP2019534246A5 JP2019512234A JP2019512234A JP2019534246A5 JP 2019534246 A5 JP2019534246 A5 JP 2019534246A5 JP 2019512234 A JP2019512234 A JP 2019512234A JP 2019512234 A JP2019512234 A JP 2019512234A JP 2019534246 A5 JP2019534246 A5 JP 2019534246A5
- Authority
- JP
- Japan
- Prior art keywords
- binding domain
- domain
- vector
- vectors
- car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013598 vector Substances 0.000 claims 55
- 239000000427 antigen Substances 0.000 claims 33
- 102000036639 antigens Human genes 0.000 claims 33
- 108091007433 antigens Proteins 0.000 claims 33
- 239000000203 mixture Substances 0.000 claims 24
- 230000004068 intracellular signaling Effects 0.000 claims 18
- 210000004698 lymphocyte Anatomy 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 230000001024 immunotherapeutic effect Effects 0.000 claims 12
- 238000009169 immunotherapy Methods 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 230000000259 anti-tumor effect Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 230000011664 signaling Effects 0.000 claims 4
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 3
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- -1 c-Met Proteins 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000002489 hematologic effect Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 2
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 2
- 102100025390 Integrin beta-2 Human genes 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims 2
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 230000008030 elimination Effects 0.000 claims 2
- 238000003379 elimination reaction Methods 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 210000000244 kidney pelvis Anatomy 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 238000012737 microarray-based gene expression Methods 0.000 claims 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 102100025221 CD70 antigen Human genes 0.000 claims 1
- 102100037904 CD9 antigen Human genes 0.000 claims 1
- 108091033409 CRISPR Proteins 0.000 claims 1
- 238000010354 CRISPR gene editing Methods 0.000 claims 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 229930186217 Glycolipid Natural products 0.000 claims 1
- 102100032558 Glypican-2 Human genes 0.000 claims 1
- 102100032530 Glypican-3 Human genes 0.000 claims 1
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 1
- 101000956427 Homo sapiens Cytokine receptor-like factor 2 Proteins 0.000 claims 1
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101001014664 Homo sapiens Glypican-2 Proteins 0.000 claims 1
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 claims 1
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 1
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 claims 1
- 101000801227 Homo sapiens Tumor necrosis factor receptor superfamily member 19 Proteins 0.000 claims 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 108090000015 Mesothelin Proteins 0.000 claims 1
- 102000003735 Mesothelin Human genes 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 1
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000032383 Soft tissue cancer Diseases 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 claims 1
- 102100033760 Tumor necrosis factor receptor superfamily member 19 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 210000000436 anus Anatomy 0.000 claims 1
- 208000003373 basosquamous carcinoma Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000000621 bronchi Anatomy 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 208000012191 childhood neoplasm Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 239000013601 cosmid vector Substances 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 208000024558 digestive system cancer Diseases 0.000 claims 1
- 210000000750 endocrine system Anatomy 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 201000010231 gastrointestinal system cancer Diseases 0.000 claims 1
- 238000012239 gene modification Methods 0.000 claims 1
- 230000005017 genetic modification Effects 0.000 claims 1
- 235000013617 genetically modified food Nutrition 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 230000010354 integration Effects 0.000 claims 1
- 230000031146 intracellular signal transduction Effects 0.000 claims 1
- 210000003228 intrahepatic bile duct Anatomy 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 101150103001 mEFG1 gene Proteins 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000011682 nervous system cancer Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000003899 penis Anatomy 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 230000009467 reduction Effects 0.000 claims 1
- 238000006722 reduction reaction Methods 0.000 claims 1
- 210000004994 reproductive system Anatomy 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 210000000626 ureter Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 210000003905 vulva Anatomy 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022100960A JP7522156B2 (ja) | 2016-09-02 | 2022-06-23 | Ｄｕｏｃａｒを用いてがんを処置するための組成物および方法 |
| JP2024110705A JP2024150518A (ja) | 2016-09-02 | 2024-07-10 | Ｄｕｏｃａｒを用いてがんを処置するための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662382791P | 2016-09-02 | 2016-09-02 | |
| US62/382,791 | 2016-09-02 | ||
| PCT/US2017/049923 WO2018045325A1 (en) | 2016-09-02 | 2017-09-01 | Compositions and methods for treating cancer with duocars |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022100960A Division JP7522156B2 (ja) | 2016-09-02 | 2022-06-23 | Ｄｕｏｃａｒを用いてがんを処置するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019534246A JP2019534246A (ja) | 2019-11-28 |
| JP2019534246A5 true JP2019534246A5 (enExample) | 2020-08-06 |
| JP7160482B2 JP7160482B2 (ja) | 2022-10-25 |
Family
ID=60022150
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019512234A Active JP7160482B2 (ja) | 2016-09-02 | 2017-09-01 | Ｄｕｏｃａｒを用いてがんを処置するための組成物および方法 |
| JP2021514984A Active JP7423610B2 (ja) | 2016-09-02 | 2019-09-18 | ＤｕｏＣＡＲでがんを処置するための組成物および方法 |
| JP2022529859A Active JP7766595B2 (ja) | 2016-09-02 | 2020-11-20 | ＤｕｏＣＡＲによりがんを処置するための組成物および方法 |
| JP2022100960A Active JP7522156B2 (ja) | 2016-09-02 | 2022-06-23 | Ｄｕｏｃａｒを用いてがんを処置するための組成物および方法 |
| JP2024005142A Pending JP2024054133A (ja) | 2016-09-02 | 2024-01-17 | ＤｕｏＣＡＲでがんを処置するための組成物および方法 |
| JP2024110705A Pending JP2024150518A (ja) | 2016-09-02 | 2024-07-10 | Ｄｕｏｃａｒを用いてがんを処置するための組成物および方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514984A Active JP7423610B2 (ja) | 2016-09-02 | 2019-09-18 | ＤｕｏＣＡＲでがんを処置するための組成物および方法 |
| JP2022529859A Active JP7766595B2 (ja) | 2016-09-02 | 2020-11-20 | ＤｕｏＣＡＲによりがんを処置するための組成物および方法 |
| JP2022100960A Active JP7522156B2 (ja) | 2016-09-02 | 2022-06-23 | Ｄｕｏｃａｒを用いてがんを処置するための組成物および方法 |
| JP2024005142A Pending JP2024054133A (ja) | 2016-09-02 | 2024-01-17 | ＤｕｏＣＡＲでがんを処置するための組成物および方法 |
| JP2024110705A Pending JP2024150518A (ja) | 2016-09-02 | 2024-07-10 | Ｄｕｏｃａｒを用いてがんを処置するための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (9) | US11453712B2 (enExample) |
| EP (4) | EP3507304B1 (enExample) |
| JP (6) | JP7160482B2 (enExample) |
| CN (5) | CN117298260A (enExample) |
| AU (4) | AU2017321894B2 (enExample) |
| CA (3) | CA3035615A1 (enExample) |
| ES (1) | ES2981703T3 (enExample) |
| WO (3) | WO2018045325A1 (enExample) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI695067B (zh) | 2013-08-05 | 2020-06-01 | 美商扭轉生物科技有限公司 | 重新合成之基因庫 |
| WO2015084513A1 (en) | 2013-12-06 | 2015-06-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same |
| EP3240805B1 (en) | 2014-12-15 | 2024-11-27 | The Regents of the University of California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
| WO2016126882A1 (en) | 2015-02-04 | 2016-08-11 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
| WO2016172377A1 (en) | 2015-04-21 | 2016-10-27 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
| CN108368482A (zh) | 2015-09-18 | 2018-08-03 | 特韦斯特生物科学公司 | 寡核酸变体文库及其合成 |
| US11512347B2 (en) | 2015-09-22 | 2022-11-29 | Twist Bioscience Corporation | Flexible substrates for nucleic acid synthesis |
| EP3184548A1 (en) | 2015-12-23 | 2017-06-28 | Miltenyi Biotec GmbH | Chimeric antigen receptor with cytokine receptor activating or blocking domain |
| CN117298260A (zh) * | 2016-09-02 | 2023-12-29 | 莱蒂恩技术公司 | 用DuoCAR治疗癌症的组合物和方法 |
| EP3516528B1 (en) | 2016-09-21 | 2025-10-15 | Atlas Data Storage, Inc. | Nucleic acid based data storage |
| JP2020508661A (ja) | 2017-02-22 | 2020-03-26 | ツイスト バイオサイエンス コーポレーション | 核酸ベースのデータ保存 |
| JP7137896B2 (ja) * | 2017-03-24 | 2022-09-15 | レンティジェン・テクノロジー・インコーポレイテッド | 抗ｃｄ３３免疫療法によりがんを処置するための組成物および方法 |
| WO2018231872A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| WO2018231864A1 (en) | 2017-06-12 | 2018-12-20 | Twist Bioscience Corporation | Methods for seamless nucleic acid assembly |
| CN111183156A (zh) * | 2017-07-31 | 2020-05-19 | 莱蒂恩技术公司 | 用于用抗cd19/cd20免疫治疗来治疗癌症的组合物和方法 |
| US11407837B2 (en) | 2017-09-11 | 2022-08-09 | Twist Bioscience Corporation | GPCR binding proteins and synthesis thereof |
| WO2019079249A1 (en) * | 2017-10-16 | 2019-04-25 | Lentigen Technology, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER WITH ANTI-CD22 IMMUNOTHERAPY |
| CA3079613A1 (en) | 2017-10-20 | 2019-04-25 | Twist Bioscience Corporation | Heated nanowells for polynucleotide synthesis |
| GB201719646D0 (en) * | 2017-11-27 | 2018-01-10 | Bivictrix Therapeutics Ltd | Therapy |
| KR20250069684A (ko) | 2018-01-04 | 2025-05-19 | 트위스트 바이오사이언스 코포레이션 | Dna 기반 디지털 정보 저장 |
| CN118957038A (zh) | 2018-05-18 | 2024-11-15 | 特韦斯特生物科学公司 | 用于核酸杂交的多核苷酸、试剂和方法 |
| WO2019246261A1 (en) * | 2018-06-19 | 2019-12-26 | Regents Of The University Of Minnesota | Genome engineering primary monocytes |
| JP7611705B2 (ja) * | 2018-06-22 | 2025-01-10 | ザ ジェネラル ホスピタル コーポレイション | Ｃｄ３７及びｃｄ１９を標的とするキメラ抗原受容体 |
| CA3104862A1 (en) * | 2018-07-03 | 2020-01-09 | Sotio, LLC | Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof |
| EP3829312A4 (en) * | 2018-08-04 | 2022-07-06 | Abcyte Therapeutics Inc. | MULTIFUNCTIONAL AND MULTI-TARGETING CAR SYSTEM AND METHODS OF USE |
| WO2020069184A2 (en) * | 2018-09-26 | 2020-04-02 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy |
| US11242389B2 (en) | 2018-09-26 | 2022-02-08 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy |
| WO2020139871A1 (en) | 2018-12-26 | 2020-07-02 | Twist Bioscience Corporation | Highly accurate de novo polynucleotide synthesis |
| CN109485734B (zh) * | 2018-12-30 | 2020-05-12 | 广州百暨基因科技有限公司 | 一种靶向bcma和cd19的双特异性嵌合抗原受体及其应用 |
| JP2022524178A (ja) * | 2019-01-07 | 2022-04-28 | セルリス パルティシパソエス リミターダ | タンデム受容体ｃａｒにおける二重特異性と腫瘍マイクロ環境を変調する方法 |
| US20220154262A1 (en) * | 2019-02-15 | 2022-05-19 | Advanced Cell Diagnostics, Inc. | Methods for multiplex detection of nucleic acids by in situ hybridization |
| EP3927735A4 (en) * | 2019-02-18 | 2023-09-06 | Memorial Sloan Kettering Cancer Center | COMBINATIONS OF MULTIPLE CHIMERIC ANTIGEN RECEPTORS FOR IMMUNOTHERAPY |
| JP2022521551A (ja) | 2019-02-26 | 2022-04-08 | ツイスト バイオサイエンス コーポレーション | Ｇｌｐ１受容体の変異体核酸ライブラリ |
| US11492728B2 (en) | 2019-02-26 | 2022-11-08 | Twist Bioscience Corporation | Variant nucleic acid libraries for antibody optimization |
| SG11202109057XA (en) | 2019-03-05 | 2021-09-29 | Nkarta Inc | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| JP7650809B2 (ja) * | 2019-03-06 | 2025-03-25 | レンティジェン・テクノロジー・インコーポレイテッド | 自己駆動型キメラ抗原受容体を用いてがんを処置するための組成物および方法 |
| JP7602475B2 (ja) * | 2019-03-08 | 2024-12-18 | オートラス リミテッド | 操作されたキメラ抗原受容体およびｃａｒの調節因子を含む組成物および方法 |
| WO2020210719A1 (en) * | 2019-04-10 | 2020-10-15 | Elevatebio Management, Inc. | Flt3-specific chimeric antigen receptors and methods of using the same |
| KR20220016083A (ko) | 2019-04-30 | 2022-02-08 | 센티 바이오사이언시스, 인코포레이티드 | 키메라 수용체 및 이의 사용 방법 |
| US20220315665A1 (en) * | 2019-05-07 | 2022-10-06 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric antigen receptors targeting glypican-2 |
| SG11202112536UA (en) * | 2019-05-16 | 2021-12-30 | Nanjing Legend Biotech Co Ltd | Engineered immune cells comprising a recognition molecule |
| US20200384029A1 (en) * | 2019-06-07 | 2020-12-10 | The Trustees Of The University Of Pennsylvania | Dual car expressing t cells individually linked to cd28 and 4-1bb |
| EP3983445A4 (en) * | 2019-06-14 | 2023-06-21 | 2seventy bio, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER |
| WO2020257612A1 (en) * | 2019-06-21 | 2020-12-24 | Twist Bioscience Corporation | Barcode-based nucleic acid sequence assembly |
| EP4001312A4 (en) * | 2019-07-18 | 2023-08-16 | JW Bioscience | ANTIBODIES SPECIFIC TO BINDING TO WRS PROTEIN AND USE THEREOF |
| CN112442509A (zh) * | 2019-08-29 | 2021-03-05 | 爱博赛特生物治疗公司 | Cd19-cd20双特异性和双通道car-t及其使用方法 |
| US12173282B2 (en) | 2019-09-23 | 2024-12-24 | Twist Bioscience, Inc. | Antibodies that bind CD3 epsilon |
| CN115003697A (zh) | 2019-09-23 | 2022-09-02 | 特韦斯特生物科学公司 | Crth2的变异核酸文库 |
| US20230131219A1 (en) * | 2019-11-08 | 2023-04-27 | The University Of North Carolina At Chapel Hill | Use of agonists to augment car t function in solid tumors |
| CN112812182B (zh) * | 2019-11-15 | 2023-01-06 | 深圳宾德生物技术有限公司 | 一种靶向fgfr4的单链抗体、嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用 |
| CN112813030A (zh) * | 2019-11-15 | 2021-05-18 | 深圳宾德生物技术有限公司 | 一种靶向fgfr4和dr5的嵌合抗原受体t细胞及其制备方法和应用 |
| PH12022551290A1 (en) * | 2019-11-26 | 2023-11-29 | Novartis Ag | Cd19 and cd22 chimeric antigen receptors and uses thereof |
| CN115551891A (zh) * | 2020-03-02 | 2022-12-30 | 加利福尼亚大学董事会 | 用于治疗癌症的嵌合抗原受体及相关方法和组合物 |
| CN116829581A (zh) * | 2020-06-22 | 2023-09-29 | 莱蒂恩技术公司 | 用于用tslpr-cd19或tslpr-cd22免疫治疗来治疗癌症的组合物和方法 |
| CN116133686A (zh) * | 2020-07-23 | 2023-05-16 | 玫帝托克斯股份有限公司 | 癌症治疗剂 |
| JP2023539245A (ja) | 2020-08-26 | 2023-09-13 | ツイスト バイオサイエンス コーポレーション | Ｇｌｐ１ｒ変異体に関する方法および組成物 |
| WO2022056490A1 (en) * | 2020-09-14 | 2022-03-17 | Vor Biopharma, Inc. | Chimeric antigen receptors for treatment of cancer |
| WO2022099026A1 (en) * | 2020-11-05 | 2022-05-12 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy |
| CN114539421B (zh) * | 2020-11-18 | 2024-03-12 | 复旦大学 | 以HIV-1 gp120与CD20为双靶点的CAR-T细胞制备方法及其应用 |
| WO2022254337A1 (en) * | 2021-06-01 | 2022-12-08 | Novartis Ag | Cd19 and cd22 chimeric antigen receptors and uses thereof |
| AU2022326908A1 (en) * | 2021-08-12 | 2024-03-28 | Cellogen Therapeutics Pvt. Ltd. | Chimeric antigen receptors (car) for b cell malignancies |
| JP2024536279A (ja) * | 2021-10-01 | 2024-10-04 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 抗体を担持した免疫細胞及び癌治療における使用方法 |
| IL313935A (en) | 2021-12-30 | 2024-08-01 | Tr1X Inc | CD4+ T cells expressing IL-10 chimeric antigen receptors and uses thereof |
| CN119923410A (zh) | 2022-07-28 | 2025-05-02 | 莱蒂恩技术公司 | 用于治疗实体瘤的嵌合抗原受体治疗 |
| AU2023320547A1 (en) * | 2022-08-04 | 2025-02-06 | Lyell Immunopharma, Inc. | Methods of manufacturing chimeric antigen receptor t cells |
| EP4331546A1 (en) | 2022-08-31 | 2024-03-06 | HyPro Innovation GmbH | Absorbent thermal effect pad |
| WO2024220598A2 (en) * | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Lentiviral vectors with two or more genomes |
| WO2025051339A1 (en) | 2023-09-05 | 2025-03-13 | Tiber Biotech Srl | SINGLE-CHAIN VARIABLE FRAGMENT AND MOLECULES DERIVING THEREFROM THAT BIND FRAGMENT TRVB5-1 OF THE β CHAIN OF HUMAN T-CELL RECEPTOR |
| EP4520346A1 (en) | 2023-09-06 | 2025-03-12 | Gyncentrum Sp. z o.o. | Cells, methods and systems for use in the treatment of a cancer with dual-car-t |
| WO2025081163A1 (en) * | 2023-10-13 | 2025-04-17 | GenCART, Inc. | Compositions for the treatment of cancer |
Family Cites Families (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US498298A (en) | 1893-05-30 | Range | ||
| US3060165A (en) | 1962-10-23 | Preparation of toxic ricin | ||
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
| US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
| US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4486414A (en) | 1983-03-21 | 1984-12-04 | Arizona Board Of Reagents | Dolastatins A and B cell growth inhibitory substances |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US5079163A (en) | 1985-03-29 | 1992-01-07 | Cetus Corporation | Recombinant ricin toxin fragments |
| US4689401A (en) | 1986-03-06 | 1987-08-25 | Cetus Corporation | Method of recovering microbially produced recombinant ricin toxin a chain |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US4816444A (en) | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5208021A (en) | 1987-10-05 | 1993-05-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of preparing diphtheria immunotoxins |
| US5792458A (en) | 1987-10-05 | 1998-08-11 | The United States Of America As Represented By The Department Of Health And Human Services | Mutant diphtheria toxin conjugates |
| IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Acylhydrazone derivatives of anthracycline and methods for their preparation |
| US5076973A (en) | 1988-10-24 | 1991-12-31 | Arizona Board Of Regents | Synthesis of dolastatin 3 |
| US4978744A (en) | 1989-01-27 | 1990-12-18 | Arizona Board Of Regents | Synthesis of dolastatin 10 |
| US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
| US4879278A (en) | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
| US4986988A (en) | 1989-05-18 | 1991-01-22 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13 |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
| US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
| US5138036A (en) | 1989-11-13 | 1992-08-11 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14 |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| JP3266311B2 (ja) | 1991-05-02 | 2002-03-18 | 生化学工業株式会社 | 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤 |
| US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| EP0630234B1 (en) | 1992-03-12 | 1997-06-11 | Alkermes Controlled Therapeutics, Inc. | Controlled release acth containing microspheres |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US6034065A (en) | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
| US5410024A (en) | 1993-01-21 | 1995-04-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| US5504191A (en) | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
| US5530097A (en) | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
| US5521284A (en) | 1994-08-01 | 1996-05-28 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides and esters |
| US5554725A (en) | 1994-09-14 | 1996-09-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthesis of dolastatin 15 |
| US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| WO1997023243A1 (en) | 1995-12-22 | 1997-07-03 | Bristol-Myers Squibb Company | Branched hydrazone linkers |
| CA2282504A1 (en) | 1997-02-25 | 1998-08-27 | Jun-Ping Xu | Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18 |
| US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
| WO2001058479A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| ES2544527T3 (es) | 2002-07-31 | 2015-09-01 | Seattle Genetics, Inc. | Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa |
| AU2004254352A1 (en) * | 2003-06-27 | 2005-01-13 | Roberto Crea | Look-through mutagenesis |
| CN103394083B (zh) | 2003-11-06 | 2017-07-18 | 西雅图基因公司 | 能够与配体偶联的单甲基缬氨酸化合物 |
| RU2402548C2 (ru) | 2004-05-19 | 2010-10-27 | Медарекс, Инк. | Химические линкеры и их конъюгаты |
| WO2011038159A2 (en) | 2009-09-24 | 2011-03-31 | Seattle Genetics, Inc. | Dr5 ligand drug conjugates |
| WO2011041093A1 (en) | 2009-10-01 | 2011-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| US20110212088A1 (en) | 2010-02-26 | 2011-09-01 | Sabbadini Roger A | Anti-paf antibodies |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US9447194B2 (en) | 2012-02-13 | 2016-09-20 | Seattle Children's Hospital | Bispecific chimeric antigen receptors and encoding polynucleotides thereof |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| WO2013176915A1 (en) | 2012-05-25 | 2013-11-28 | Roman Galetto | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| US10117896B2 (en) | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| AU2013335180B2 (en) * | 2012-10-24 | 2018-07-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | M971 chimeric antigen receptors |
| US9217807B2 (en) | 2013-07-23 | 2015-12-22 | Schlumberger Technology Corporation | Systems and methods for identifying sanding in production wells using time-lapse sonic data |
| RU2717984C2 (ru) | 2013-11-21 | 2020-03-27 | ЮСиЭл БИЗНЕС ЛТД | Клетка |
| WO2015084513A1 (en) | 2013-12-06 | 2015-06-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same |
| JP6698546B2 (ja) | 2014-04-14 | 2020-05-27 | セレクティスＣｅｌｌｅｃｔｉｓ | 癌免疫療法のためのｂｃｍａ（ｃｄ２６９）特異的キメラ抗原受容体 |
| CN106536564B (zh) | 2014-06-02 | 2021-08-31 | 美国卫生和人力服务部 | 靶向cd-19的嵌合抗原受体 |
| MX390943B (es) * | 2014-07-21 | 2025-03-21 | Novartis Ag | Receptores de antígeno quimérico cd33 y usos de los mismos. |
| CN114107424A (zh) | 2014-10-08 | 2022-03-01 | 诺华股份有限公司 | 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途 |
| EP3018200A1 (en) * | 2014-11-07 | 2016-05-11 | Fondazione Matilde Tettamanti e Menotti de Machi Onlus | Improved method for the generation of genetically modified cells |
| EP3240805B1 (en) | 2014-12-15 | 2024-11-27 | The Regents of the University of California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
| KR102376242B1 (ko) * | 2014-12-24 | 2022-03-21 | 오토러스 리미티드 | 세포 |
| WO2016172537A1 (en) | 2015-04-23 | 2016-10-27 | The Trustees Of The University Of Pennsylvania | Compositions to disrupt protein kinase a anchoring and uses thereof |
| PE20180241A1 (es) * | 2015-04-30 | 2018-01-31 | Psioxus Therapeutics Ltd | Adenovirus oncolitico que codifica una proteina b7 |
| WO2016179283A1 (en) * | 2015-05-05 | 2016-11-10 | Fate Therapeutics, Inc. | Modulation of t lymphocytes |
| US10639329B2 (en) * | 2015-06-12 | 2020-05-05 | Lentigen Technology, Inc. | Method to treat cancer with engineered T-cells |
| SG10201913682QA (en) * | 2015-06-25 | 2020-03-30 | Icell Gene Therapeutics Llc | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF |
| DK3313874T3 (da) * | 2015-06-26 | 2021-05-03 | Univ Southern California | Maskering af kimære antigen-receptor t-celler til tumorspecifik aktivering |
| JP6821688B2 (ja) | 2015-10-09 | 2021-01-27 | ミルテニー・バイオテク・テクノロジー・インコーポレイテッドＭｉｌｔｅｎｙｉ Ｂｉｏｔｅｃ Ｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． | キメラ抗原受容体および使用方法 |
| CN105331586B (zh) | 2015-11-20 | 2020-09-15 | 上海细胞治疗研究院 | 一种包含高效杀伤启动机制的肿瘤精准t细胞及其用途 |
| WO2017153555A1 (en) | 2016-03-11 | 2017-09-14 | Harmonic Pharma | Sublingual compositions comprising natural extracts and uses thereof |
| CN117298260A (zh) | 2016-09-02 | 2023-12-29 | 莱蒂恩技术公司 | 用DuoCAR治疗癌症的组合物和方法 |
| JP7137896B2 (ja) | 2017-03-24 | 2022-09-15 | レンティジェン・テクノロジー・インコーポレイテッド | 抗ｃｄ３３免疫療法によりがんを処置するための組成物および方法 |
| CN108220247A (zh) * | 2018-03-20 | 2018-06-29 | 杭州史迪姆生物科技有限公司 | 一种双car-t细胞及其制备方法和应用 |
-
2017
- 2017-09-01 CN CN202311164481.5A patent/CN117298260A/zh active Pending
- 2017-09-01 CA CA3035615A patent/CA3035615A1/en active Pending
- 2017-09-01 US US16/078,269 patent/US11453712B2/en active Active
- 2017-09-01 WO PCT/US2017/049923 patent/WO2018045325A1/en not_active Ceased
- 2017-09-01 CN CN201780061243.8A patent/CN109843922B/zh active Active
- 2017-09-01 ES ES17780539T patent/ES2981703T3/es active Active
- 2017-09-01 JP JP2019512234A patent/JP7160482B2/ja active Active
- 2017-09-01 AU AU2017321894A patent/AU2017321894B2/en active Active
- 2017-09-01 EP EP17780539.7A patent/EP3507304B1/en active Active
- 2017-09-01 EP EP23184693.2A patent/EP4282969A3/en active Pending
-
2018
- 2018-09-18 US US16/134,735 patent/US10689431B2/en active Active
-
2019
- 2019-09-18 CA CA3113194A patent/CA3113194A1/en active Pending
- 2019-09-18 AU AU2019342730A patent/AU2019342730A1/en active Pending
- 2019-09-18 EP EP19790096.2A patent/EP3852789A2/en active Pending
- 2019-09-18 CN CN202410358222.4A patent/CN118370808A/zh active Pending
- 2019-09-18 JP JP2021514984A patent/JP7423610B2/ja active Active
- 2019-09-18 CN CN201980072801.XA patent/CN113382745B/zh active Active
- 2019-09-18 WO PCT/US2019/051734 patent/WO2020061194A2/en not_active Ceased
- 2019-11-22 US US16/692,957 patent/US11208455B2/en active Active
-
2020
- 2020-06-22 US US16/907,713 patent/US11802142B2/en active Active
- 2020-11-20 WO PCT/US2020/061623 patent/WO2021102337A1/en not_active Ceased
- 2020-11-20 AU AU2020386636A patent/AU2020386636A1/en active Pending
- 2020-11-20 CN CN202080092701.6A patent/CN115768462A/zh active Pending
- 2020-11-20 JP JP2022529859A patent/JP7766595B2/ja active Active
- 2020-11-20 CA CA3158878A patent/CA3158878A1/en active Pending
- 2020-11-20 EP EP20825051.4A patent/EP4061407A1/en active Pending
-
2021
- 2021-12-02 US US17/540,377 patent/US12365718B2/en active Active
-
2022
- 2022-05-25 US US17/752,966 patent/US20220281946A1/en active Pending
- 2022-06-23 JP JP2022100960A patent/JP7522156B2/ja active Active
-
2023
- 2023-07-06 US US18/347,644 patent/US20240025962A1/en active Pending
- 2023-09-12 US US18/465,233 patent/US20240043497A1/en active Pending
-
2024
- 2024-01-17 JP JP2024005142A patent/JP2024054133A/ja active Pending
- 2024-07-10 JP JP2024110705A patent/JP2024150518A/ja active Pending
-
2025
- 2025-01-24 AU AU2025200478A patent/AU2025200478A1/en active Pending
- 2025-06-17 US US19/240,490 patent/US20250367291A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534246A5 (enExample) | ||
| JPWO2021102337A5 (enExample) | ||
| US20250034244A1 (en) | Bicistronic chimeric antigen receptors and their uses | |
| JP7179041B2 (ja) | 三官能性ｔ細胞－抗原カプラ及び方法並びにこれらの使用 | |
| JP7267321B2 (ja) | 改善された特異性を有する改変型ｔリンパ球 | |
| JP7177794B2 (ja) | 抗ｔｒｂｃ１抗原結合ドメイン | |
| JP7162530B2 (ja) | 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞 | |
| CN113227379A (zh) | 多功能多靶向嵌合抗原受体（car）系统及其使用方法 | |
| JP7000315B2 (ja) | 高結合活性ｈｐｖ ｔ細胞受容体 | |
| ES2905557T3 (es) | Receptor de antígeno quimérico anti-CD30 y su uso | |
| JP7662588B2 (ja) | 遺伝子操作された薬物耐性ｔ細胞およびその使用方法 | |
| Orentas et al. | Immunotherapy targets in pediatric cancer | |
| WO2019109980A1 (zh) | 嵌合蛋白、表达嵌合蛋白的免疫效应细胞及其应用 | |
| CN110520524A (zh) | 靶向肿瘤微环境的嵌合抗原受体t细胞 | |
| JP2020530989A5 (enExample) | ||
| KR20190101979A (ko) | 합성 면역 수용체 및 이의 사용 방법 | |
| CA3093705A1 (en) | Anti-gucy2c chimeric antigen receptor compositions and methods | |
| KR20150063145A (ko) | 면역치료용 조성물 및 방법 | |
| JP2015525765A (ja) | Ｃａｒｔ細胞を調節するための組成物および方法 | |
| JP7404279B2 (ja) | 様々な構築物最適化を備えたｔ細胞抗原カプラ | |
| Chmielewski et al. | T cells redirected by a CD3ζ chimeric antigen receptor can establish self-antigen-specific tumour protection in the long term | |
| CN112442509A (zh) | Cd19-cd20双特异性和双通道car-t及其使用方法 | |
| JPWO2020181164A5 (enExample) | ||
| Heard et al. | Advances in CAR design | |
| CN114438033A (zh) | 靶向pd-1h（vista）的抗肿瘤免疫治疗方法 |